Moderna shares more than doubled Wednesday after it announced initial results from a study of an experimental cancer treatment that would be the first of its kind if approved by regulators. Moderna and Merck are developing a treatment using an mRNA-based cancer vaccine called intismeran that is designed to be tailored to individual patients based [...]
| # | Наименование новости | Тональность | Информативность | Дата публикации |
|---|---|---|---|---|
| 1 | Moderna's cancer vaccine cuts melanoma recurrence risk in early trial: What we know | 0 | 7.73 | 26-08-2026 |
| 2 | Moderna saluée par Wall Street pour l’efficacité promise d’un traitement utilisant l’ARN messager contre le cancer de la peau | 0 | 8.33 | 20-08-2026 |
| 3 | Kommentar: Modernas Studienerfolg ist ein Durchbruch im Kampf gegen Krebs | 0 | 7.12 | 20-08-2026 |
| 4 | 🔥 Персональная вакцина от рака показала эффективность в III фазе ... | 0 | 8.53 | 20-08-2026 |
| 5 | Personalized cancer vaccine shows positive late-stage trial results | 0 | 14.35 | 19-08-2026 |
| 6 | Акции Moderna взлетели на 160% после успешного испытания вакцины от рака | 0 | 11.8 | 19-08-2026 |
| 7 | Moderna Aktie mit Kursrallye nach Hautkrebs Studie, auch Biontech profitiert | 0 | 13.87 | 20-08-2026 |
| 8 | Interactive: A cancer vaccine is being tailored to individuals | 0 | 12.1 | 19-08-2026 |
| 9 | Pandemic darlings Moderna, BioNTech are now on two different paths | 0 | 7 | 31-07-2025 |